41 results on '"Wang, Chih-To"'
Search Results
2. Federated learning for predicting clinical outcomes in patients with COVID-19
- Author
-
Dayan, Ittai, Roth, Holger R, Zhong, Aoxiao, Harouni, Ahmed, Gentili, Amilcare, Abidin, Anas Z, Liu, Andrew, Costa, Anthony Beardsworth, Wood, Bradford J, Tsai, Chien-Sung, Wang, Chih-Hung, Hsu, Chun-Nan, Lee, CK, Ruan, Peiying, Xu, Daguang, Wu, Dufan, Huang, Eddie, Kitamura, Felipe Campos, Lacey, Griffin, de Antônio Corradi, Gustavo César, Nino, Gustavo, Shin, Hao-Hsin, Obinata, Hirofumi, Ren, Hui, Crane, Jason C, Tetreault, Jesse, Guan, Jiahui, Garrett, John W, Kaggie, Joshua D, Park, Jung Gil, Dreyer, Keith, Juluru, Krishna, Kersten, Kristopher, Rockenbach, Marcio Aloisio Bezerra Cavalcanti, Linguraru, Marius George, Haider, Masoom A, AbdelMaseeh, Meena, Rieke, Nicola, Damasceno, Pablo F, e Silva, Pedro Mario Cruz, Wang, Pochuan, Xu, Sheng, Kawano, Shuichi, Sriswasdi, Sira, Park, Soo Young, Grist, Thomas M, Buch, Varun, Jantarabenjakul, Watsamon, Wang, Weichung, Tak, Won Young, Li, Xiang, Lin, Xihong, Kwon, Young Joon, Quraini, Abood, Feng, Andrew, Priest, Andrew N, Turkbey, Baris, Glicksberg, Benjamin, Bizzo, Bernardo, Kim, Byung Seok, Tor-Díez, Carlos, Lee, Chia-Cheng, Hsu, Chia-Jung, Lin, Chin, Lai, Chiu-Ling, Hess, Christopher P, Compas, Colin, Bhatia, Deepeksha, Oermann, Eric K, Leibovitz, Evan, Sasaki, Hisashi, Mori, Hitoshi, Yang, Isaac, Sohn, Jae Ho, Murthy, Krishna Nand Keshava, Fu, Li-Chen, de Mendonça, Matheus Ribeiro Furtado, Fralick, Mike, Kang, Min Kyu, Adil, Mohammad, Gangai, Natalie, Vateekul, Peerapon, Elnajjar, Pierre, Hickman, Sarah, Majumdar, Sharmila, McLeod, Shelley L, Reed, Sheridan, Gräf, Stefan, Harmon, Stephanie, Kodama, Tatsuya, Puthanakit, Thanyawee, Mazzulli, Tony, de Lavor, Vitor Lima, Rakvongthai, Yothin, Lee, Yu Rim, Wen, Yuhong, Gilbert, Fiona J, Flores, Mona G, and Li, Quanzheng
- Subjects
Patient Safety ,Good Health and Well Being ,COVID-19 ,Electronic Health Records ,Humans ,Machine Learning ,Outcome Assessment ,Health Care ,Prognosis ,SARS-CoV-2 ,Medical and Health Sciences ,Immunology - Abstract
Federated learning (FL) is a method used for training artificial intelligence models with data from multiple sources while maintaining data anonymity, thus removing many barriers to data sharing. Here we used data from 20 institutes across the globe to train a FL model, called EXAM (electronic medical record (EMR) chest X-ray AI model), that predicts the future oxygen requirements of symptomatic patients with COVID-19 using inputs of vital signs, laboratory data and chest X-rays. EXAM achieved an average area under the curve (AUC) >0.92 for predicting outcomes at 24 and 72 h from the time of initial presentation to the emergency room, and it provided 16% improvement in average AUC measured across all participating sites and an average increase in generalizability of 38% when compared with models trained at a single site using that site's data. For prediction of mechanical ventilation treatment or death at 24 h at the largest independent test site, EXAM achieved a sensitivity of 0.950 and specificity of 0.882. In this study, FL facilitated rapid data science collaboration without data exchange and generated a model that generalized across heterogeneous, unharmonized datasets for prediction of clinical outcomes in patients with COVID-19, setting the stage for the broader use of FL in healthcare.
- Published
- 2021
3. LGR5 in breast cancer and ductal carcinoma in situ: a diagnostic and prognostic biomarker and a therapeutic target
- Author
-
Hagerling, Catharina, Owyong, Mark, Sitarama, Vaishnavi, Wang, Chih-Yang, Lin, Charlene, van den Bijgaart, Renske JE, Koopman, Charlotte D, Brenot, Audrey, Nanjaraj, Ankitha, Wärnberg, Fredrik, Jirström, Karin, Klein, Ophir D, Werb, Zena, and Plaks, Vicki
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Immunology ,Breast Cancer ,Biotechnology ,Prevention ,Cancer ,Adult ,Aged ,Aged ,80 and over ,Animals ,Biomarkers ,Tumor ,Breast Neoplasms ,Carcinoma ,Intraductal ,Noninfiltrating ,Cell Line ,Tumor ,Female ,Heterografts ,Humans ,Mice ,Middle Aged ,Prognosis ,RNA ,Neoplasm ,Real-Time Polymerase Chain Reaction ,Receptor ,ErbB-2 ,Receptors ,G-Protein-Coupled ,Tissue Array Analysis ,LGR5 ,Breast cancer ,DCIS ,Estrogen receptor ,Targeted therapy ,Receptor ,erbB-2 ,Public Health and Health Services ,Oncology & Carcinogenesis ,Oncology and carcinogenesis ,Epidemiology - Abstract
BackgroundNovel biomarkers are required to discern between breast tumors that should be targeted for treatment from those that would never become clinically apparent and/or life threatening for patients. Moreover, therapeutics that specifically target breast cancer (BC) cells with tumor-initiating capacity to prevent recurrence are an unmet need. We investigated the clinical importance of LGR5 in BC and ductal carcinoma in situ (DCIS) to explore LGR5 as a biomarker and a therapeutic target.MethodsWe stained BC (n = 401) and DCIS (n = 119) tissue microarrays with an antibody against LGR5. We examined an LGR5 knockdown ER- cell line that was orthotopically transplanted and used for in vitro colony assays. We also determined the tumor-initiating role of Lgr5 in lineage-tracing experiments. Lastly, we transplanted ER- patient-derived xenografts into mice that were subsequently treated with a LGR5 antibody drug conjugate (anti-LGR5-ADC).ResultsLGR5 expression correlated with small tumor size, lower grade, lymph node negativity, and ER-positivity. ER+ patients with LGR5high tumors rarely had recurrence, while high-grade ER- patients with LGR5high expression recurred and died due to BC more often. Intriguingly, all the DCIS patients who later died of BC had LGR5-positive tumors. Colony assays and xenograft experiments substantiated a role for LGR5 in ER- tumor initiation and subsequent growth, which was further validated by lineage-tracing experiments in ER- /triple-negative BC mouse models. Importantly, by utilizing LGR5high patient-derived xenografts, we showed that anti-LGR5-ADC should be considered as a therapeutic for high-grade ER- BC.ConclusionLGR5 has distinct roles in ER- vs. ER+ BC with potential clinical applicability as a biomarker to identify patients in need of therapy and could serve as a therapeutic target for high-grade ER- BC.
- Published
- 2020
4. RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer
- Author
-
Gbenedio, Oghenekevwe M, Bonnans, Caroline, Grun, Delphine, Wang, Chih-Yang, Hatch, Ace J, Mahoney, Michelle R, Barras, David, Matli, Mary, Miao, Yi, Garcia, K Christopher, Tejpar, Sabine, Delorenzi, Mauro, Venook, Alan P, Nixon, Andrew B, Warren, Robert S, Roose, Jeroen P, and Depeille, Philippe
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Immunology ,Colo-Rectal Cancer ,Cancer ,Digestive Diseases ,4.1 Discovery and preclinical testing of markers and technologies ,Detection ,screening and diagnosis ,Good Health and Well Being ,Animals ,Antineoplastic Agents ,Immunological ,Biomarkers ,Tumor ,Cell Proliferation ,Cetuximab ,Clinical Trials as Topic ,Colorectal Neoplasms ,Computational Biology ,DNA-Binding Proteins ,Datasets as Topic ,Disease Models ,Animal ,Disease Progression ,Disease-Free Survival ,ErbB Receptors ,Guanine Nucleotide Exchange Factors ,Humans ,Kaplan-Meier Estimate ,Mice ,Mice ,Knockout ,Primary Cell Culture ,Prognosis ,Signal Transduction ,Spheroids ,Cellular ,Tumor Cells ,Cultured ,Tumor Suppressor Proteins ,Colorectal cancer ,Drug therapy ,Gastroenterology ,Signal transduction ,Therapeutics ,Biomedical and clinical sciences ,Health sciences - Abstract
Colorectal cancer (CRC) is the third most frequent neoplastic disorder and is a main cause of tumor-related mortality as many patients progress to stage IV metastatic CRC. Standard care consists of combination chemotherapy (FOLFIRI or FOLFOX). Patients with WT KRAS typing are eligible to receive anti-EGFR therapy combined with chemotherapy. Unfortunately, predicting efficacy of CRC anti-EGFR therapy has remained challenging. Here we uncover that the EGFR-pathway component RasGRP1 acts as CRC tumor suppressor in the context of aberrant Wnt signaling. We find that RasGRP1 suppresses EGF-driven proliferation of colonic epithelial organoids. Having established that RasGRP1 dosage levels impacts biology, we focused on CRC patients next. Mining five different data platforms, we establish that RasGRP1 expression levels decrease with CRC progression and predict poor clinical outcome of patients. Lastly, deletion of one or two Rasgrp1 alleles makes CRC spheroids more susceptible to EGFR inhibition. Retrospective analysis of the CALGB80203 clinical trial shows that addition of anti-EGFR therapy to chemotherapy significantly improves outcome for CRC patients when tumors express low RasGRP1 suppressor levels. In sum, RasGRP1 is a unique biomarker positioned in the EGFR pathway and of potential relevance to anti-EGFR therapy for CRC patients.
- Published
- 2019
5. Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study.
- Author
-
Jang, Tyng‐Yuan, Liang, Po‐Cheng, Jun, Dae Won, Jung, Jang Han, Toyoda, Hidenori, Wang, Chih‐Wen, Yuen, Man‐Fung, Cheung, Ka Shing, Yasuda, Satoshi, Kim, Sung Eun, Yoon, Eileen L, An, Jihyun, Enomoto, Masaru, Kozuka, Ritsuzo, Chuma, Makoto, Nozaki, Akito, Ishikawa, Toru, Watanabe, Tsunamasa, Atsukawa, Masanori, and Arai, Taeang
- Subjects
CHRONIC hepatitis B ,DNA viruses ,PROPENSITY score matching ,HEPATITIS B virus ,TENOFOVIR - Abstract
Background and Aim: The benefits of entecavir (ETV) versus tenofovir disoproxil fumarate (TDF) in reducing the development of chronic hepatitis B (CHB)‐related hepatocellular carcinoma remain controversial. Whether mortality rates differ between patients with CHB treated with ETV and those treated with TDF is unclear. Methods: A total of 2542 patients with CHB treated with either ETV or TDF were recruited from a multinational cohort. A 1:1 propensity score matching was performed to balance the differences in baseline characteristics between the two patient groups. We aimed to compare the all‐cause, liver‐related, and non‐liver‐related mortality between patients receiving ETV and those receiving TDF. Results: The annual incidence of all‐cause mortality in the entire cohort was 1.0/100 person‐years (follow‐up, 15 757.5 person‐years). Patients who received TDF were younger and had a higher body mass index, platelet count, hepatitis B virus deoxyribonucleic acid levels, and proportion of hepatitis B e‐antigen seropositivity than those who received ETV. The factors associated with all‐cause mortality were fibrosis‐4 index > 6.5 (hazard ratio [HR]/confidence interval [CI]: 3.13/2.15–4.54, P < 0.001), age per year increase (HR/CI: 1.05/1.04–1.07, P < 0.001), alanine aminotransferase level per U/L increase (HR/CI: 0.997/0.996–0.999, P = 0.003), and γ‐glutamyl transferase level per U/L increase (HR/CI: 1.002/1.001–1.003, P < 0.001). No significant difference in all‐cause mortality was observed between the ETV and TDF groups (log–rank test, P = 0.69). After propensity score matching, no significant differences in all‐cause, liver‐related, or non‐liver‐related mortality were observed between the two groups. Conclusions: Long‐term outcomes of all‐cause mortality and liver‐related and non‐liver‐related mortality did not differ between patients treated with ETV and those receiving TDF. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Deciphering the Prognostic Efficacy of MRI Radiomics in Nasopharyngeal Carcinoma: A Comprehensive Meta-Analysis.
- Author
-
Wang, Chih-Keng, Wang, Ting-Wei, Lu, Chia-Fung, Wu, Yu-Te, and Hua, Man-Wei
- Subjects
- *
RADIOMICS , *NASOPHARYNX cancer , *OVERALL survival , *MAGNETIC resonance imaging , *PROGNOSIS - Abstract
This meta-analysis investigates the prognostic value of MRI-based radiomics in nasopharyngeal carcinoma treatment outcomes, specifically focusing on overall survival (OS) variability. The study protocol was registered with INPLASY (INPLASY202420101). Initially, a systematic review identified 15 relevant studies involving 6243 patients through a comprehensive search across PubMed, Embase, and Web of Science, adhering to PRISMA guidelines. The methodological quality was assessed using the Quality in Prognosis Studies (QUIPS) tool and the Radiomics Quality Score (RQS), highlighting a low risk of bias in most domains. Our analysis revealed a significant average concordance index (c-index) of 72% across studies, indicating the potential of radiomics in clinical prognostication. However, moderate heterogeneity was observed, particularly in OS predictions. Subgroup analyses and meta-regression identified validation methods and radiomics software as significant heterogeneity moderators. Notably, the number of features in the prognosis model correlated positively with its performance. These findings suggest radiomics' promising role in enhancing cancer treatment strategies, though the observed heterogeneity and potential biases call for cautious interpretation and standardization in future research. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Comparative Analysis of the GNAI Family Genes in Glioblastoma through Transcriptomics and Single-Cell Technologies.
- Author
-
Raza, Ahmad, Yen, Meng-Chi, Anuraga, Gangga, Shahzadi, Iram, Mazhar, Muhammad Waqar, Ta, Hoang Dang Khoa, Xuan, Do Thi Minh, Dey, Sanskriti, Kumar, Sachin, Santoso, Adrian Wangsawijaya, William, Bianca Tobias, and Wang, Chih-Yang
- Subjects
PROTEIN analysis ,BIOMARKERS ,STATISTICS ,CANCER invasiveness ,GLIOMAS ,CELL receptors ,CELL physiology ,CELLULAR signal transduction ,T-test (Statistics) ,PEARSON correlation (Statistics) ,GENOMES ,GENE expression profiling ,RESEARCH funding ,MEMBRANE proteins ,ONTOLOGIES (Information retrieval) ,DATA analysis - Abstract
Simple Summary: In this study, we aimed to address the critical need for a prognostic biomarker in the treatment of GBM. Various approaches and treatments have been examined in the recent literature; however, their effectiveness is limited due to the highly invasive, heterogeneous, and resistant nature of GBM tumors. TCGA, which is a database available online, was used to assess the role of guanine nucleotide-binding protein G(i) subunit alpha 3 (GNAI3), with a focus on analyzing its impact across different WHO grades. The results revealed that GNAI3 is associated with a poor prognosis and is involved in significantly important pathways, such as macrophage maturation and cytoskeleton arrangements. These findings suggest that GNAI3 may serve as a valuable prognostic biomarker for the GBM microenvironment and could provide actionable information for the treatment of GBM. Glioblastoma multiforme (GBM) is one of the most aggressive cancers with a low overall survival rate. The treatment of GBM is challenging due to the presence of the blood–brain barrier (BBB), which hinders drug delivery. Invasive procedures alone are not effective at completely removing such tumors. Hence, identifying the crucial pathways and biomarkers for the treatment of GBM is of prime importance. We conducted this study to identify the pathways associated with GBM. We used The Cancer Genome Atlas (TCGA) GBM genomic dataset to identify differentially expressed genes (DEGs). We investigated the prognostic values of the guanine nucleotide-binding protein G(i) alpha subunit (GNAI) family of genes in GBM using a Chinese Glioma Genome Atlas (CGGA) dataset. Within this dataset, we observed the association in the tumor microenvironment between the gene expression of GNAI subunit 3 (GNAI3) and a poor prognosis. MetaCore and gene ontology (GO) analyses were conducted to explore the role of GNAI3 in co-expressed genes and associated signaling pathways using a transcript analysis. Notable pathways included "Cytoskeleton remodeling regulation of actin cytoskeleton organization by the kinase effectors of Rho GTPases" and "Immune response B cell antigen receptor (BCR) pathway". A single-cell analysis was used to assess GNAI3 expression in GBM. The results demonstrated that GNAI family genes, specifically GNAI3, were significantly associated with carcinogenesis and malignancy in GBM patients. Our findings suggest that the GNAI3 gene holds potential as a prognostic biomarker for GBM. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma.
- Author
-
Chen, Yen-Hao, Tsai, Ching-Hua, Chen, Yen-Yang, Wang, Chih-Chi, Wang, Jing-Houng, Hung, Chao-Hung, and Kuo, Yuan-Hung
- Subjects
NIVOLUMAB ,HEPATOCELLULAR carcinoma ,PEMBROLIZUMAB ,PROGNOSIS ,LIVER cancer - Abstract
Background: Nivolumab and pembrolizumab have not been directly compared in clinical trials, and the aim of this study is to investigate the efficacy and safety of nivolumab versus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) in real-world practice. Methods: We retrospectively reviewed patients with HCC who received intravenous nivolumab or pembrolizumab alone as second-line and later therapy. The objective response was determined according to the Response Evaluation Criteria in Solid Tumors criteria version 1.1. Adverse events (AEs) were graded based on the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. The Kaplan–Meier method was used to analyze progression-free survival (PFS) and overall survival (OS). Prognostic values were estimated using hazard ratios with 95% confidence intervals (CIs). Results: In total, 120 patients were enrolled, including 95 who received nivolumab and 25 who received pembrolizumab. All patients were staged as Barcelona Clinic Liver Cancer stage C, and 29 patients were classified as Child-Pugh classification B (7). The response rate of the pembrolizumab and nivolumab groups were 8.0% and 7.4%, respectively. There was no significant difference in the median PFS between the pembrolizumab and nivolumab groups (2.7 months versus 2.9 months). The median OS in the nivolumab group was longer than that in the pembrolizumab group (10.8 months versus 8.1 months); however, the difference was not statistically significant. The effects of pembrolizumab and nivolumab on the median PFS and OS were consistent across the subgroups based on baseline characteristics. The severity of all AEs was grades 1–2 without treatment interruption or dose adjustment; there was no statistically significant difference in the incidence of treatment-related AEs between these two groups. Additionally, the percentage of patients receiving subsequent therapy was consistent between the two groups. Conclusion: The efficacy and safety of pembrolizumab and nivolumab were comparable in the management of patients with pretreated HCC in real-world practice. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Penetrating Exploration of Prognostic Correlations of the FKBP Gene Family with Lung Adenocarcinoma.
- Author
-
Wang, Chin-Chou, Shen, Wan-Jou, Anuraga, Gangga, Hsieh, Yu-Hsiu, Khoa Ta, Hoang Dang, Xuan, Do Thi Minh, Shen, Chiu-Fan, Wang, Chih-Yang, and Wang, Wei-Jan
- Subjects
GENE families ,ISOMERASES ,CYCLOPHILINS ,UBIQUINONES ,ELECTRON transport ,PROGNOSIS ,PROTEIN folding ,GENETIC transcription regulation - Abstract
The complexity of lung adenocarcinoma (LUAD), the development of which involves many interacting biological processes, makes it difficult to find therapeutic biomarkers for treatment. FK506-binding proteins (FKBPs) are composed of 12 members classified as conservative intracellular immunophilin family proteins, which are often connected to cyclophilin structures by tetratricopeptide repeat domains and have peptidyl prolyl isomerase activity that catalyzes proline from residues and turns the trans form into the cis form. Since FKBPs belong to chaperone molecules and promote protein folding, previous studies demonstrated that FKBP family members significantly contribute to the degradation of damaged, misfolded, abnormal, and foreign proteins. However, transcript expressions of this gene family in LUAD still need to be more fully investigated. In this research, we adopted high-throughput bioinformatics technology to analyze FKBP family genes in LUAD to provide credible information to clinicians and promote the development of novel cancer target drugs in the future. The current data revealed that the messenger (m)RNA levels of FKBP2, FKBP3, FKBP4, FKBP10, FKBP11, and FKBP14 were overexpressed in LUAD, and FKBP10 had connections to poor prognoses among LUAD patients in an overall survival (OS) analysis. Based on the above results, we selected FKBP10 to further conduct a comprehensive analysis of the downstream pathway and network. Through a DAVID analysis, we found that FKBP10 was involved in mitochondrial electron transport, NADH to ubiquinone transport, mitochondrial respiratory chain complex I assembly, etc. The MetaCore pathway analysis also indicated that FKBP10 was involved in "Ubiquinone metabolism", "Translation_(L)-selenoaminoacid incorporation in proteins during translation", and "Transcription_Negative regulation of HIF1A function". Collectively, this study revealed that FKBP family members are both significant prognostic biomarkers for lung cancer progression and promising clinical therapeutic targets, thus providing new targets for treating LUAD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Novel Potential Therapeutic Targets of PTPN Families for Lung Cancer.
- Author
-
Wang, Chin-Chou, Shen, Wan-Jou, Anuraga, Gangga, Khoa Ta, Hoang Dang, Xuan, Do Thi Minh, Chen, Sih-Tong, Shen, Chiu-Fan, Jiang, Jia-Zhen, Sun, Zhengda, Wang, Chih-Yang, and Wang, Wei-Jan
- Subjects
LUNG cancer ,PROTEIN-tyrosine phosphatase ,DRUG target ,MITOGEN-activated protein kinases ,BIOLOGICAL systems ,PROGNOSIS - Abstract
Despite the treatment of lung adenocarcinoma (LUAD) having partially improved in recent years, LUAD patients still have poor prognosis rates. Therefore, it is especially important to explore effective biomarkers and exploit novel therapeutic developments. High-throughput technologies are widely used as systematic approaches to explore differences in expressions of thousands of genes for both biological and genomic systems. Recently, using big data analyses in biomedicine research by integrating several high-throughput databases and tools, including The Cancer Genome Atlas (TCGA), cBioportal, Oncomine, and Kaplan–Meier plotter, is an important strategy to identify novel biomarkers for cancer therapy. Here, we used two different comprehensive bioinformatics analysis and revealed protein tyrosine phosphatase non-receptor type (PTPN) family genes, especially PTPN1 and PTPN22, were downregulated in lung cancer tissue in comparison with normal samples. The survival curves indicated that LUAD patients with high transcription levels of PTPN5 were significantly associated with a good prognosis. Meanwhile, Gene Ontology (GO) and MetaCore analyses indicated that co-expression of the PTPN1, PTPN5, and PTPN21 genes was significantly enriched in cancer development-related pathways, including GTPase activity, regulation of small GTPase-mediated signal transduction, response to mechanical stimuli, vasculogenesis, organ morphogenesis, regulation of stress fiber assembly, mitogen-activated protein kinase (MAPK) cascade, cell migration, and angiogenesis. Collectively, this study revealed that PTPN family members are both significant prognostic biomarkers for lung cancer progression and promising clinical therapeutic targets, which provide new targets for treating LUAD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Prospective role and immunotherapeutic targets of sideroflexin protein family in lung adenocarcinoma: evidence from bioinformatics validation.
- Author
-
Dang, Huy Hoang, Ta, Hoang Dang Khoa, Nguyen, Truc T. T., Anuraga, Gangga, Wang, Chih-Yang, Lee, Kuen-Haur, and Le, Nguyen Quoc Khanh
- Subjects
PROGNOSIS ,OVERALL survival ,ADENOCARCINOMA ,SURVIVAL rate ,IRON metabolism ,IRON-based superconductors - Abstract
As lung cancer remains the leading cause of cancer deaths globally, characterizing the tumor molecular profiles is crucial to tailoring treatments for individuals at advanced stages. Cancer cells exhibit strong dependence on iron for their proliferation, and several iron-regulatory proteins have been proposed as either oncogenes or tumor suppressive genes. This study aims to evaluate the prospective therapeutic and prognostic values of the sideroflexin (SFXN) gene family, whose functions involve mitochondrial iron metabolism, in lung adenocarcinoma (LUAD). Differential expression analysis using TIMER and UALCAN tools was first employed to compare SFXNs expression levels between normal and LUAD tissues. Next, SFXNs' prognostic values, biological significance, and potential as immunotherapy candidates were examined from GEPIA, cBioPortal, MetaCore, Cytoscape, and TIMER databases. It was found that all members of SFXN family, except SFXN3, were differentially expressed in LUAD compared to normal samples and within different stages of LUAD. Survival analysis then revealed SFXN1 to be related to worse overall survival outcome in patients with LUAD. Furthermore, several correlations between expression of SFXN1 and immune infiltration cells were discovered. To conclude, our study provides evidence of SFXN family gene's relevance to the prognosis and immunotherapeutic targets of LUAD. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Platinum Plus Tegafur–Uracil versus Platinum Alone during Concurrent Chemoradiotherapy in Patients with Nonmetastatic Nasopharyngeal Carcinoma: A Propensity-Score-Matching Analysis.
- Author
-
Lien, Ching-Feng, Wang, Chien-Chung, Yang, Chuan-Chien, Wang, Chih-Chun, Hwang, Tzer-Zen, Shih, Yu-Chen, Yeh, Shyh-An, and Hsieh, Meng-Che
- Subjects
THERAPEUTIC use of antineoplastic agents ,NASOPHARYNX cancer ,MULTIVARIATE analysis ,METASTASIS ,CASE-control method ,CANCER relapse ,PLATINUM ,FLUOROURACIL ,CHEMORADIOTHERAPY ,TREATMENT effectiveness ,CANCER patients ,KAPLAN-Meier estimator ,DESCRIPTIVE statistics ,SURVIVAL analysis (Biometry) - Published
- 2022
- Full Text
- View/download PDF
13. Validation of the 7th Edition TNM Staging System for Hepatocellular Carcinoma: An Analysis of 8,828 Patients in a Single Medical Center
- Author
-
Kee, Kwong-Ming, Wang, Jing-Houng, Lin, Chih-Yun, Wang, Chih-Chi, Cheng, Yu-Fan, and Lu, Sheng-Nan
- Published
- 2013
- Full Text
- View/download PDF
14. Treatment Sequences in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Cetuximab Followed by Immunotherapy or Vice Versa.
- Author
-
Yang, Chuan-Chien, Lien, Ching-Feng, Hwang, Tzer-Zen, Wang, Chih-Chun, Wang, Chien-Chung, Shih, Yu-Chen, Yeh, Shyh-An, and Hsieh, Meng-Che
- Subjects
THERAPEUTIC use of monoclonal antibodies ,SCIENTIFIC observation ,MULTIVARIATE analysis ,HEAD & neck cancer ,TREATMENT effectiveness ,CANCER patients ,KAPLAN-Meier estimator ,SURVIVAL analysis (Biometry) ,DESCRIPTIVE statistics ,PROGRESSION-free survival ,SQUAMOUS cell carcinoma ,IMMUNOTHERAPY - Abstract
Simple Summary: As the treatment advances, there were several novel agents developed for R/M HNSCC, including an anti-epidermal growth factor receptor antibody, cetuximab, and an anti-programmed death-1 immune checkpoint inhibitor, pembrolizumab and nivolumab. To date, little was known regarding the optimal treatment sequences. Our observational study demonstrated that median overall survival was 23.7 months versus 22.8 months in Cet-IO and IO-Cet, respectively (p = 0.484). The overall response rate (ORR) were 73% in Cet-IO versus 37% in IO-Cet (p = 0.002). Both Cet-IO and IO-Cet are effective in R/M HNSCC patients with insignificant survival differences. The higher response rate of Cet-IO might render it to be considered in patients with large tumor burdens and urgent needs for treatment responses. Our conclusion can be real-world evidence for clinical decision-making. Background: The prognosis was poor when patients had recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Herein, we conducted an observational study of cetuximab followed by immunotherapy (Cet-IO) versus immunotherapy followed by cetuximab (IO-Cet) in patients with R/M HNSCC. Methods: Patients who were diagnosed with R/M HNSCC and treated with a sequential cetuximab-containing regimen and immunotherapy-containing regimen were enrolled in our study. Kaplan-Meier curves were estimated for progression-free survival (PFS) and overall survival (OS). Results: A total of 75 patients were enrolled in our study for oncologic outcomes evaluation, with 40 patients in Cet-IO and 35 patients in IO-Cet. The median PFS1 was 5.1 months in Cet-IO and 4.5 months in IO-Cet (p = 0.777) and the median PFS2 was 16.5 months in Cet-IO and 11.4 months in IO-Cet (p = 0.566). The median OS was 23.7 months versus 22.8 months in Cet-IO and IO-Cet, respectively (p = 0.484). The overall response rate (ORR) were 73% in Cet-IO versus 37% in IO-Cet (p = 0.002). Multivariate analysis demonstrated that the treatment sequences, Cet-IO or IO-Cet, were insignificantly different with survival. Conclusion: Both Cet-IO and IO-Cet are effective in R/M HNSCC patients with insignificant survival differences. The higher ORR of Cet-IO might render it to be considered in patients with large tumor burdens and urgent needs for treatment responses. Further prospective studies are merited to validate our conclusions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Risk assessment and prognostic analysis of patients with splenic infarction in emergency department: a multicenter retrospective study.
- Author
-
Yen, Chieh-Ching, Wang, Chih-Kai, Chen, Shou-Yen, Gao, Shi-Ying, Lo, Hsiang-Yun, Ng, Chip-Jin, and Chaou, Chung-Hsien
- Subjects
- *
INFARCTION , *PROGNOSIS , *MEDICAL personnel , *BLOOD diseases , *HOSPITAL emergency services , *INFECTIVE endocarditis , *MONONUCLEOSIS , *ATRIAL fibrillation - Abstract
Splenic infarction is a thromboembolic disease that is frequently missed in acute settings. Previous reviews were rarely presented from a clinical perspective. We aimed to evaluate the clinical characteristics, risk factors with diagnostic value, and prognostic factors using large cohort data and a matched case–control study method. A retrospective medical record review of six hospitals in Taiwan from January 1, 2005, to August 31, 2020, was conducted. All patients who underwent contrast CT with confirmed the diagnosis of splenic infarction were included. Their characteristics were presented and compared to a matched control group with similar presenting characteristics. Prognostic factors were also analyzed. A total of 130 cases were included, two-thirds of whom presented with abdominal pain. Atrial fibrillation was the most common associated predisposing condition, followed by hematologic disease. A higher proportion of tachycardia, positive qSOFA score, history of hypertension or atrial fibrillation, leukocytosis, and thrombocytopenia were found in splenic infarction patients compared to their counterparts. An underlying etiology of infective endocarditis was associated with a higher proportion of ICU admission. Splenic infarction patients often presented with left upper abdominal pain and tachycardia. A history of hypertension, atrial fibrillation, a laboratory result of leukocytosis or thrombocytopenia may provide a clue for clinicians to include splenic infarction in the differential list. Among the patients diagnosed with splenic infarction, those with an underlying etiology of infectious endocarditis may be prone to deterioration or ICU admission. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. Impact of tumor disappearance ratio on the prognosis of lung adenocarcinoma ≤2 cm in size: A retrospective cohort study.
- Author
-
Wu, Jia-Jun, Wu, Chih-Ying, Wu, Ching-Yang, Wang, Chih-Liang, Yang, Tsung-Ying, Tseng, Jeng-Sen, Hsu, Kuo-Hsuan, Huang, Yen-Hsiang, Hsu, Chung-Ping, Chuang, Cheng-Yen, Lin, Chih-Hung, Tseng, Chien-Hua, Chen, Kun-Chieh, and Chang, Gee-Chen
- Subjects
COMPUTED tomography ,ADENOCARCINOMA ,PROGNOSIS ,DIAGNOSIS ,LUNGS ,PAIN measurement ,LUNG tumors ,RETROSPECTIVE studies ,PSYCHOLOGICAL tests - Abstract
Background/purpose: Lung cancer patients can have advanced-stages at diagnosis, even the tumor size is ≤2 cm. We aimed to study the relationship between image characteristics, clinical, and patholoigcal results.Methods: We retrospectively enrolled patients with lung adenocarcinoma at Taichung Veterans General Hospital and Chang Gung Memorial Hospital from 2007 to 2015, who were diagnosed with treatment naïve primary tumor lesions at sizes less than 2 cm, as measured by computed tomography (CT) scans. The patient was analyzed for lymph node (LN) and distant metastasis evaluation, with clinicopathological characteristics, including tumor-disappearance ratio (TDR) (tumor diameter at the mediastinal/lung window) over chest CT scans, pathological diagnosis, disease-free survival (DFS), and overall survival (OS).Results: Totally 280 patients were surveyed initially and showed significantly increase of clinical LN involvement and distant metastasis when TDR ≤75% compared with >75% (21.6% vs 0% for LN involvement; 27.1% vs 0% for distant metastasis; both p < 0.001). We included 199 patients having surgical treatment and follow-up for the survival analysis. With a TDR ≤75%, significantly worse DFS (HR, 19.23; 95% CI, 2.60-142.01; p = 0.004) and a trend of worse OS (HR, 4.97; 95% CI, 0.61-40.61; p = 0.134) were noted by Kaplan-Meier method. TDR ≤75% revealed more advanced pathological stage, and more tumors containing micropapillary or solid subtypes when diagnosed adenocarcinoma.Conclusion: For lung cancer patients with primary tumor ≤2 cm, TDR ≤75% was related to more advanced stages, the presence of micropapillary or solid components of adenocarcinoma subtypes, worse DFS, and a trend of worse OS. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
17. Prognosis after resection of single large hepatocellular carcinoma: Results from an Asian high-volume liver surgery center.
- Author
-
Liu, Yueh-Wei, Lin, Chih-Che, Yong, Chee-Chien, Wang, Chih-Chi, Chen, Chao-Long, Wang, Jing-Houng, and Yen, Yi-Hao
- Subjects
LIVER surgery ,HEPATOCELLULAR carcinoma ,PROPENSITY score matching ,LIVER cancer ,PROGNOSIS ,WESTERN countries - Abstract
Background & aims: In 2012, the Barcelona Clinic Liver Cancer (BCLC) system designated a single large hepatocellular carcinoma (SLHCC) (>5 cm) as BCLC stage A rather than stage B. However, a recent study from western countries reported that prognosis following liver resection (LR) among patients with SLHCC was similar to that among patients with BCLC stage B. We aim to evaluate the prognosis following LR among patients with SLHCC from an Asian high-volume liver surgery center. Methods: Patients who underwent curative-intent LR for histologically proven HCC between 2011 and 2017 were enrolled using an HCC registry database. Overall survival (OS) among patients with BCLC stages 0, A, and B was examined. Patients with a SLHCC were classified as BCLC stage A1. Results: Among 543 patients, 89 (16.4%) were BCLC stage 0, 289 (53.2%) were BCLC stage A, 92 (16.9%) were BCLC stage A1, and 73 (13.4%) were BCLC stage B. The median follow-up was 38 months. The five-year OS rates among patients with BCLC stages 0, A, A1, and B were 83.5%, 83.7%, 77.4%, and 55.4%, respectively (p<0.001). No difference in OS was noted for patients with BCLC stage A versus A1 (p = 0.11), even after adjusting for competing factors (hazard ratio = 0.97, 95% confidence interval = 0.53–1.79; p = 0.93). Conclusion: Prognosis following LR among patients with SLHCC was similar to that among patients with BCLC stage A. The prognosis for SLHCC should thus be considered comparable to that for BCLC stage A. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
18. Neuroprognostic accuracy of blood biomarkers for post-cardiac arrest patients: A systematic review and meta-analysis.
- Author
-
Wang, Chih-Hung, Chang, Wei-Tien, Su, Ke-Ing, Huang, Chien-Hua, Tsai, Min-Shan, Chou, Eric, Lu, Tsung-Chien, Chen, Wen-Jone, Lee, Chien-Chang, and Chen, Shyr-Chyr
- Subjects
- *
META-analysis , *BIOMARKERS , *AUTOMATED external defibrillation , *FIXED effects model , *CARDIAC arrest , *PUBLICATION bias , *BRAIN injuries , *INDUCED hypothermia , *SYSTEMATIC reviews , *PROGNOSIS , *ENZYMES , *CALCIUM-binding proteins , *PROBABILITY theory - Abstract
Aim: To summarise and compare the prognostic accuracy of the blood biomarkers of brain injury, including NSE and S-100B, for neurological outcomes in adult post-cardiac arrest patients.Methods: We systematically searched PubMed and Embase databases from their inception to March 2019. We selected studies providing sufficient data of prognostic values of NSE or S-100B to predict neurological outcomes in adult post-cardiac arrest patients. We adopted QUADAS-2 to assess risk of bias and a Bayesian bivariate random-effects meta-analysis model to synthesise the prognostic data. The study protocol was registered with PROSPERO (CRD42018084933).Results: We included 42 studies involving 4806 patients in the meta-analysis. The NSE was associated with a pooled sensitivity of 0.56 (95% credible interval [CrI], 0.47-0.65) and pooled specificity of 0.99 (95% CrI, 0.98-1.00). The S-100B was associated with a pooled sensitivity of 0.63 (95% CrI, 0.46-0.78) and pooled specificity of 0.97 (95% CrI, 0.92-1.00). The heterogeneity for NSE (I2, 22.4%) and S-100B (I2, 16.1%) was low and publication bias was not significant. In subgroup analyses, both biomarkers were associated with high specificity across all subgroups with regard to different populations (i.e. whether patients were out-of-hospital cardiac arrest or whether patients received targeted temperature management), different timings of measurement, and different timings of outcome assessment.Conclusions: The prognostic performance was comparable between NSE and S-100B. Both biomarkers may be integrated into a multimodal neuroprognostication algorithm for post-cardiac arrest patients and institution-specific cut-off points for both biomarkers should be established. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
19. Metabolic tumor volume predicts overall survival in patients with primary pulmonary lymphoepithelioma-like carcinoma.
- Author
-
Lin, Chun-Yu, Chang, Yu-Chuan, Wang, I-Ting, Hsieh, Meng-Heng, Wang, Chih-Wei, Lin, Shu-Min, Wu, Ching-Yang, and Fang, Yueh-Fu
- Subjects
POSITRON emission tomography ,COMPUTED tomography ,CARCINOMA ,TUMOR classification ,EPSTEIN-Barr virus - Abstract
Pretreatment tumor metabolic burden, measured using fluorine-18 fluorodeoxyglucose positron emission tomography/computerized tomography (
18 F-FDG PET/CT), has been demonstrated to predict outcomes in various types of malignancies. Additionally, Epstein-Barr virus (EBV) serum titer is associated with stages of pulmonary lymphoepithelioma-like carcinoma (LELC). The present study aimed to investigate the prognostic value of the functional parameters of18 F-FDG PET/CT in pulmonary LELC and their association with serum EBV DNA. The present retrospective study analyzed data from 71 patients with pulmonary LELC; among these, 32 patients with pulmonary LELC underwent pretreatment18 F-FDG PET/CT staging between January 2008 and December 2016. EBV viral load and functional parameters of18 F-FDG PET/CT were used for survival analysis. Multivariate analysis identified tumor stage IV as a significant predictor of poor progression-free survival [hazard ratio (HR), 4.85; P=0.049], whereas elevated total metabolic tumor volume (MTV ≥72.6 ml) independently predicted worse overall survival (OS; HR, 12.59; P=0.024). Pretreatment serum EBV DNA titer was significantly positively associated with total MTV (P=0.0337) and total lesion glycolysis (TLG; P=0.0093), but could not predict outcomes. Total MTV was an independent predictor of OS, and may guide clinical management for pulmonary LELC. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
20. Modulating effects of immediate neuroprognosis on early coronary angiography and targeted temperature management following out-of-hospital cardiac arrest: A retrospective cohort study.
- Author
-
Wang, Chih-Hung, Tsai, Min-Shan, Chang, Wei-Tien, Yu, Ping-Hsun, Wu, Yen-Wen, Huang, Chien-Hua, and Chen, Wen-Jone
- Subjects
- *
CORONARY angiography , *CARDIAC arrest , *LOGISTIC regression analysis , *COHORT analysis , *RETROSPECTIVE studies , *PROGNOSIS - Abstract
Aim: The simplified cardiac arrest hospital prognosis (sCAHP) score is a validated tool for predicting neurological outcomes after out-of-hospital cardiac arrest (OHCA). We used the sCAHP score to evaluate whether the effects of early coronary angiography (CAG) and targeted temperature management (TTM) for OHCA were modulated by immediate neuroprognosis.Methods: This was a single-centre retrospective observational study. Consecutive OHCA patients were screened between 2011 and 2017. Multivariate logistic regression analysis and generalised additive models (GAMs) were used to examine the associations between independent variables and outcomes. Early CAG was defined as CAG performed within 24 h after return of spontaneous circulation (ROSC).Results: A total of 412 patients were included in the study, and 94 (22.8%) patients had neurologically intact survival. The GAM plot identified a sCAHP score of 185 as the cut-off point to differentiate high-risk (sCAHP score ≧185) from low-risk (sCAHP score <185) patients. Regression models indicated that early CAG was significantly associated with favourable neurological [odds ratio (OR) 4.43, 95% confidence interval (CI) 2.28-8.60, p < 0.001] and survival outcomes (OR 3.47, 95% CI 1.93-6.25, p < 0.001), independent of the sCAHP score. Although TTM was associated with favourable neurological outcome only in low-risk patients (OR 2.13, 95% CI 1.10-4.13, p = 0.02), TTM was associated with improved survival for all patients (OR 2.66, 95% CI 1.54-4.59, p < 0.001), independent of the sCAHP score.Conclusions: Early CAG and TTM should be considered for all OHCA patients as suggested by guidelines, irrespective of the immediately predicted neuroprognosis after ROSC. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
21. Differential Expression Pattern of THBS1 and THBS2 in Lung Cancer: Clinical Outcome and a Systematic-Analysis of Microarray Databases.
- Author
-
Weng, Tzu-Yang, Wang, Chih-Yang, Hung, Yu-Hsuan, Chen, Wei-Ching, Chen, Yi-Ling, and Lai, Ming-Derg
- Subjects
- *
LUNG cancer & genetics , *LUNG cancer diagnosis , *GENE expression , *THROMBOSPONDINS , *MICROARRAY technology - Abstract
Thrombospondin 1 and thrombospondin 2 (THBS1 and THBS2) share similar multifunctional domains, and are known to be antiangiogenic. However, the expression pattern of THBS1 and THBS2 is different, and the specific role of THBS2 in different subtypes of lung cancer remains largely unclear. To evaluate the significance of THBS1 and THBS2 in the development of lung cancer, the present study performed a microarray-based systematic-analysis to determine the transcript levels of thrombospondins and their relation to the prognosis in lung cancer. THBS1 was in general underexpressed in lung cancer; in contrast, mRNA levels of THBS2 were markedly overexpressed in a number of datasets of non-small cell lung carcinoma (NSCLC), including lung adenocarcinoma (AC) and squamous cell carcinoma. Similar expression pattern of THBS1 and THBS2 was verified in pulmonary AC cell lines with real-time PCR analysis. The survival of lung AC patients with high THBS2 mRNA expression levels was poorer than patients with low levels of expression of THBS2. In a microarray-based analysis, genes coexpressed with THBS1 or THBS2 were determined. Pulmonary AC patients with a high expression level of sevenTSHB1-coexpressed genes (CCL5, CDH11, FYB, GZMK, LA-DQA1, PDE4DIP, and SELL) had better survival rates than those with a low expression level. Patients with a high expression of seven TSHB2-coexpressed genes (CHI3L1, COL5A2, COL11A1, FAP, MXRA5, THY1, and VCAN) had poor survival rates. Downregulation of VCAN and THBS2 with shRNA inhibited the cell proliferation in the A549 cell line. In summary, THBS1 functions as a tumor suppressor in lung adenocarcinoma. However, THBS2 may play a double-edged role in the progression of lung AC, i.e. anti-angiogenic and oncogenic function. Further study on the mechanism underlying the activity of THBS2 is warranted to have further implications for cancer diagnosis and treatment of pulmonary AC. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
22. Peroxiredoxin 1 induces inflammatory cytokine response and predicts outcome of cardiogenic shock patients necessitating extracorporeal membrane oxygenation: an observational cohort study and translational approach.
- Author
-
Chia-Hsiung Liu, Shuenn-Wen Kuo, Li-Ming Hsu, Shu-Chien Huang, Chih-Hsien Wang, Pi-Ru Tsai, Yih-Sharng Chen, Tzuu-Shuh Jou, Wen-Je Ko, Liu, Chia-Hsiung, Kuo, Shuenn-Wen, Hsu, Li-Ming, Huang, Shu-Chien, Wang, Chih-Hsien, Tsai, Pi-Ru, Chen, Yih-Sharng, Jou, Tzuu-Shuh, and Ko, Wen-Je
- Subjects
PATIENT satisfaction ,MYOCARDIAL infarction ,CARDIOGENIC shock ,CYTOKINES ,PROGNOSIS ,CELL receptors ,CELLULAR signal transduction ,EXTRACORPOREAL membrane oxygenation ,INFLAMMATORY mediators ,LONGITUDINAL method ,MACROPHAGES ,MEDICAL research ,MONOCYTES ,OXIDOREDUCTASES ,THERAPEUTICS - Abstract
Background: Extracellular peroxiredoxin 1 (Prdx1) has been implicated to play a pivotal role in regulating inflammation; however, its function in tissue hypoxia-induced inflammation, such as severe cardiogenic shock patients, has not yet been defined. Thus, the objective of this study was to test the hypothesis that Prdx1 possesses prognostic value and instigates systemic inflammatory response syndrome in cardiogenic shock patients undergoing extracorporeal membrane oxygenation (ECMO) support.Methods: We documented the early time course evolution of circulatory Prdx1, hypoxic marker carbonic anhydrase IX, inflammatory cytokines including IL-6, IL-8, IL-10, MCP-1, TNF-α, IL-1β, and danger signaling receptors (TLR4 and CD14) in a cohort of cardiogenic shock patients within 1 day after ECMO support. In vitro investigations employing cultured murine macrophage cell lines and human monocytes were applied to clarify the relationship between Prdx1 and inflammatory response.Results: Prdx1 not only peaked earlier than all the other cytokines we studied during the initial course, but also predicted a worse outcome in patients who had higher initial Prdx1 plasma levels. The Prdx1 levels in patients positively correlated with hypoxic markers carbonic anhydrase IX and lactate, and inflammatory cytokines. In vitro study demonstrated that hypoxia/reoxygenation induced Prdx1 release from human monocytes and enhanced the responsiveness of the monocytes in Prdx1-induced cytokine secretions. Furthermore, functional inhibition by Prdx1 antibody implicated a crucial role of Prdx1 in hypoxia/reoxygenation-induced IL-6 secretion.Conclusions: Prdx1 release during the early phase of ECMO support in cardiogenic shock patients is associated with the development of systemic inflammatory response syndrome and poor clinical outcomes. Thus, circulating Prdx1 provides not only prognostic information but may be a promising target against ischemia/reperfusion injury. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
23. A Retrospective Review of the Prognostic Value of ALDH-1, Bmi-1 and Nanog Stem Cell Markers in Esophageal Squamous Cell Carcinoma.
- Author
-
Hwang, Cheng-Cheng, Nieh, Shin, Lai, Chien-Hong, Tsai, Chien-Sheng, Chang, Liang-Che, Hua, Chung-Ching, Chi, Wen-Ying, Chien, Hui-Ping, Wang, Chih-Wei, Chan, Siu-Cheung, Hsieh, Tsan-Yu, and Chen, Jim-Ray
- Subjects
RETROSPECTIVE studies ,ALDEHYDE dehydrogenase ,STEM cells ,BIOMARKERS ,ESOPHAGEAL cancer ,IMMUNOHISTOCHEMISTRY ,PROGNOSIS - Abstract
Stem cell markers are upregulated in various cancers and have potential as prognostic indicators. The objective of this study was to determine the expression of three stem cell markers, aldehyde dehydrogenase 1 (ALDH-1), B cell-specific Moloney murine leukemia virus integration site 1 (Bmi-1), and Nanog, in esophageal squamous cell carcinoma (ESCC) tissues. Immunohistochemistry was used to measure the expression of ALDH-1, Bmi-1, and Nanog in ESCC tissues from 41 patients who received pre-operative chemoradiation. We evaluated the relationship between expression of these markers, and clinicopathological features, tumor regression grade (TRG), and 5-year overall survival (OS). There were no significant associations of ALDH-1 or Bmi-1 expression with age, gender, clinical stage, and treatments (p>0.05). However, patients with Nanog-positive tumors were significantly older than those whose tumors were Nanog-negative (p = 0.033). TRG after treatment was significantly associated with expression of ALDH-1 (p = 0.001), Bmi-1 (p = 0.004), and Nanog (p<0.001). Although OS was significantly better in patients with low TRGs (p = 0.001), there were no significant correlations between ALDH-1, Bmi-1, or Nanog with OS. Expression of ALDH-1, Bmi-1, and Nanog correlated with TRG, but not OS. Further large studies are necessary to fully elucidate the prognostic value of these stem cell markers for ESCC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
24. Overexpression of caldesmon is associated with lymph node metastasis and poorer prognosis in patients with oral cavity squamous cell carcinoma.
- Author
-
Chang, Kai‐Ping, Wang, Chih‐Lueh Albert, Kao, Huang‐Kai, Liang, Ying, Liu, Shiau‐Chin, Huang, Ling‐Ling, Hseuh, Chuen, Hsieh, Ya‐Ju, Chien, Kun‐Yi, Chang, Yu‐Sun, Yu, Jau‐Song, and Chi, Lang‐Ming
- Subjects
- *
LYMPH node cancer , *SQUAMOUS cell carcinoma , *CALDESMON , *IMMUNOHISTOCHEMISTRY , *REVERSE transcriptase polymerase chain reaction , *CANCER invasiveness , *PATIENTS , *PROGNOSIS - Abstract
BACKGROUND A previous comparative tissue proteomics study by the authors of the current study led to the identification of caldesmon (CaD) as one of the proteins associated with cervical metastasis of oral cavity squamous cell carcinoma (OSCC). In the current investigation, the authors focused on the potential functions of CaD in patients with OSCC. METHODS CaD expression was examined in tissue samples from 155 patients using immunohistochemical analysis. The expression of CaD variants was determined by Western blot analysis and reverse transcriptase-polymerase chain reaction. In addition, the specific effects of CaD gene overexpression and silence were determined in OSCC cell lines. RESULTS CaD expression was found to be significantly higher in tumor cells from metastatic lymph nodes compared with primary tumor cells, and was nearly absent in normal oral epithelia. Higher CaD expression was found to be correlated with positive N classification, poor differentiation, perineural invasion, and tumor depth ( P = .001, P = .029, P = .001, and P = .031, respectively). In survival analyses, OSCC patients with higher CaD expression were found to have poorer prognosis with regard to disease-specific survival and disease-free survival ( P = .003 and P = .014, respectively). Multivariate analyses further indicated that higher CaD expression was an independent predictor of disease-specific survival ( P = .043). Serum CaD levels were found to be significantly higher in patients with OSCC, but this finding was not associated with clinicopathological manifestations. Data obtained from in vitro suppression, rescue, and overexpression of CaD in OEC-M1 cells indicated that CaD promotes migration and invasive processes in OSCC cells. CONCLUSIONS The findings of the current study collectively suggest that the low-molecular-weight CaD expression in OSCC tumors is associated with tumor metastasis and patient survival. Cancer 2013;119:4003-4011. © 2013 American Cancer Society. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
25. Artificial Intelligence-Enabled Electrocardiogram Estimates Left Atrium Enlargement as a Predictor of Future Cardiovascular Disease.
- Author
-
Lou, Yu-Sheng, Lin, Chin-Sheng, Fang, Wen-Hui, Lee, Chia-Cheng, Ho, Ching-Liang, Wang, Chih-Hung, and Lin, Chin
- Subjects
CARDIOVASCULAR diseases ,LEFT heart atrium ,ATRIAL fibrillation ,PROGNOSIS ,MEDICAL screening ,NOMOGRAPHY (Mathematics) - Abstract
Background: Left atrium enlargement (LAE) can be used as a predictor of future cardiovascular diseases, including hypertension (HTN) and atrial fibrillation (Afib). Typical electrocardiogram (ECG) changes have been reported in patients with LAE. This study developed a deep learning model (DLM)-enabled ECG system to identify patients with LAE. Method: Patients who had ECG records with corresponding echocardiography (ECHO) were included. There were 101,077 ECGs, 20,510 ECGs, 7611 ECGs, and 11,753 ECGs in the development, tuning, internal validation, and external validation sets, respectively. We evaluated the performance of a DLM-enabled ECG for diagnosing LAE and explored the prognostic value of ECG-LAE for new-onset HTN, new-onset stroke (STK), new-onset mitral regurgitation (MR), and new-onset Afib. Results: The DLM-enabled ECG achieved AUCs of 0.8127/0.8176 for diagnosing mild LAE, 0.8587/0.8688 for diagnosing moderate LAE, and 0.8899/0.8990 for diagnosing severe LAE in the internal/external validation sets. Notably, ECG-LAE had higher prognostic value compared to ECHO-LAE, which had C-indices of 0.711/0.714 compared to 0.695/0.692 for new-onset HTN, 0.676/0.688 compared to 0.663/0.677 for new-onset STK, 0.696/0.695 compared to 0.676/0.673 for new-onset MR, and 0.800/0.806 compared to 0.786/0.760 for new-onset Afib in internal/external validation sets, respectively. Conclusions: A DLM-enabled ECG could be considered as a LAE screening tool and provide better prognostic information for related cardiovascular diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. A Clinical Study of Prognosis and Glucocorticoid Pulse Treatment in Patients with Acute Paraquat Intoxication.
- Author
-
Tsai, Jen-Pi, Lee, Ru-Ping, Wang, Chih-Hsien, Fang, Te-Chao, and Hsu, Bang-Gee
- Abstract
Abstract: Objective: Paraquat is a highly toxic herbicide that binds strongly to tissue and causes high mortality rates due to pesticide intoxication in Taiwan. In this study, we evaluated the usefulness of methylprednisolone pulse therapy and calculation of the severity index of paraquat poisoning (SIPP) to predict the prognosis in patients with oral paraquat intoxication Materials and Methods: Thirty-two patients with paraquat poisoning from January 2003 to April 2005 were enrolled into this study at a medical center in eastern Taiwan. All 32 patients had history of oral intake of paraquat and urine paraquat was positive at the emergency department. Time of oral intake of paraquat and serum paraquat levels were assayed at the emergency department for calculating SIPP (hour × mg/L) level. Sixteen patients with oral paraquat poisoning were treated with intravenous methylprednisolone 1 g/day and charcoal hemoperfusion for 3 days (MP group), and 16 patients with oral paraquat poisoning were treated with charcoal hemoperfusion only for 3 days (control group). Results: The mortality rate of the patients with oral paraquat poisoning was high (87.5%). There were no statistically significant differences in death (p = 1.000), age (p = 0.706), sex (p = 0.069), serum blood urea nitrogen (p= 0.104), creatinine (p= 0.174), aspartate aminotransferase (p= 0.083), alanine aminotransferase (p = 0.365), plasma level of paraquat (p = 0.880) and SIPP level (p = 0.734) between the MP group and control group. Young age (p = 0.030), lower initial plasma paraquat level (p = 0.002), lower serum creatinine (p = 0.009), female sex (p = 0.033), lower elapsed time from ingestion of paraquat to arrival at hospital (p = 0.035) and SIPP level less than 10 (p < 0.001) were associated with survival in patients with oral paraquat poisoning. Multivariate forward stepwise linear regression analysis of deaths showed that SIPP > 10 (hour × mg/L) (p < 0.001) was an independent predictor of death in patients with oral paraquat poisoning and explained 77.1% of the variance (R
2 = 0.771). Conclusion: Treatment with methylprednisolone pulse therapy did not show better results in patients with acute oral paraquat poisoning. SIPP was an independent predictor of death in patients with oral paraquat poisoning. [Copyright &y& Elsevier]- Published
- 2009
- Full Text
- View/download PDF
27. Novel Insights into the Prognosis and Immunological Value of the SLC35A (Solute Carrier 35A) Family Genes in Human Breast Cancer.
- Author
-
Ta, Hoang Dang Khoa, Minh Xuan, Do Thi, Tang, Wan-Chun, Anuraga, Gangga, Ni, Yi-Chun, Pan, Syu-Ruei, Wu, Yung-Fu, Fitriani, Fenny, Putri Hermanto, Elvira Mustikawati, Athoillah, Muhammad, Andriani, Vivin, Ajiningrum, Purity Sabila, Wang, Chih-Yang, and Lee, Kuen-Haur
- Subjects
EPIDERMAL growth factor receptors ,BRCA genes ,GENE families ,CANCER relapse ,CANCER cell growth ,HEAT shock proteins ,PROGNOSIS ,KAPLAN-Meier estimator - Abstract
According to statistics 2020, female breast cancer (BRCA) became the most commonly diagnosed malignancy worldwide. Prognosis of BRCA patients is still poor, especially in population with advanced or metastatic. Particular functions of each members of the solute carrier 35A (SLC35A) gene family in human BRCA are still unknown regardless of awareness that they play critical roles in tumorigenesis and progression. Using integrated bioinformatics analyses to identify therapeutic targets for specific cancers based on transcriptomics, proteomics, and high-throughput sequencing, we obtained new information and a better understanding of potential underlying molecular mechanisms. Leveraging BRCA dataset that belongs to The Cancer Genome Atlas (TCGA), which were employed to clarify SLC35A gene expression levels. Then we used a bioinformatics approach to investigate biological processes connected to SLC35A family genes in BRCA development. Beside that, the Kaplan–Meier estimator was leveraged to explore predictive values of SLC35A family genes in BCRA patients. Among individuals of this family gene, expression levels of SLC35A2 were substantially related to poor prognostic values, result from a hazard ratio of 1.3 (with 95 percent confidence interval (95% CI: 1.18–1.44), the p for trend (ptrend) is 3.1 × 10
−7 ). Furthermore, a functional enrichment analysis showed that SLC35A2 was correlated with hypoxia-inducible factor 1A (HIF1A), heat shock protein (HSP), E2 transcription factor (E2F), DNA damage, and cell cycle-related signaling. Infiltration levels observed in specific types of immune cell, especially the cluster of differentiation found on macrophages and neutrophils, were positively linked with SLC35A2 expression in multiple BRCA subclasses (luminal A, luminal B, basal, and human epidermal growth factor receptor 2). Collectively, SLC35A2 expression was associated with a lower recurrence-free survival rate, suggesting that it could be used as a biomarker in treating BRCA. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
28. Potential Prognostic Biomarkers of OSBPL Family Genes in Patients with Pancreatic Ductal Adenocarcinoma.
- Author
-
Chou, Cheng-Wei, Hsieh, Yu-Hsiu, Ku, Su-Chi, Shen, Wan-Jou, Anuraga, Gangga, Khoa Ta, Hoang Dang, Lee, Kuen-Haur, Lee, Yu-Cheng, Lin, Cheng-Hsien, Wang, Chih-Yang, and Wang, Wei-Jan
- Subjects
PANCREATIC duct ,PROGNOSIS ,PATIENT-family relations ,PATIENTS' families ,CELLULAR signal transduction ,GENE families - Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal malignancy with poor survival outcomes. In addition, oxysterol-binding protein-like (OSBPL) family members are reported to be involved in lipid binding and transport and play critical roles in tumorigenesis. However, relationships between PDAC and OSBPL family members have not comprehensively been elucidated. In this study, we used the Oncomine and GEPIA 2 databases to analyze OSBPL transcription expressions in PDAC. The Kaplan–Meier plotter and TIMER 2.0 were used to assess the relationships between overall survival (OS) and immune-infiltration with OSBPL family members. Co-expression data from cBioPortal were downloaded to assess the correlated pathways with OSBPL gene family members using DAVID. The expressions of OSBPL3, OSBPL8, OSBPL10, and OSBPL11 were found to be highly upregulated in PDAC. Low expressions of OSBPL3, OSBPL8, and OSBPL10 indicated longer OS. The functions of OSBPL family members were mainly associated with several potential signaling pathways in cancer cells, including ATP binding, integrin binding, receptor binding, and the renin-angiotensin system (RAS) signaling pathway. The transcription levels of OSBPL gene family members were connected with several immune infiltrates. Collectively, OSBPL family members are influential biomarkers for the early diagnosis of PDAC and have prognostic value, with the promise of precise treatment of PDAC in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
29. Potential Prognostic Biomarkers of NIMA (Never in Mitosis, Gene A)-Related Kinase (NEK) Family Members in Breast Cancer.
- Author
-
Anuraga, Gangga, Wang, Wei-Jan, Phan, Nam Nhut, An Ton, Nu Thuy, Ta, Hoang Dang Khoa, Berenice Prayugo, Fidelia, Minh Xuan, Do Thi, Ku, Su-Chi, Wu, Yung-Fu, Andriani, Vivin, Athoillah, Muhammad, Lee, Kuen-Haur, and Wang, Chih-Yang
- Subjects
PROGNOSIS ,CANCER prognosis ,BRCA genes ,BREAST cancer ,BREAST cancer prognosis - Abstract
Breast cancer remains the most common malignant cancer in women, with a staggering incidence of two million cases annually worldwide; therefore, it is crucial to explore novel biomarkers to assess the diagnosis and prognosis of breast cancer patients. NIMA-related kinase (NEK) protein kinase contains 11 family members named NEK1-NEK11, which were discovered from Aspergillus Nidulans; however, the role of NEK family genes for tumor development remains unclear and requires additional study. In the present study, we investigate the prognosis relationships of NEK family genes for breast cancer development, as well as the gene expression signature via the bioinformatics approach. The results of several integrative analyses revealed that most of the NEK family genes are overexpressed in breast cancer. Among these family genes, NEK2/6/8 overexpression had poor prognostic significance in distant metastasis-free survival (DMFS) in breast cancer patients. Meanwhile, NEK2/6 had the highest level of DNA methylation, and the functional enrichment analysis from MetaCore and Gene Set Enrichment Analysis (GSEA) suggested that NEK2 was associated with the cell cycle, G2M checkpoint, DNA repair, E2F, MYC, MTORC1, and interferon-related signaling. Moreover, Tumor Immune Estimation Resource (TIMER) results showed that the transcriptional levels of NEK2 were positively correlated with immune infiltration of B cells and CD4
+ T Cell. Collectively, the current study indicated that NEK family genes, especially NEK2 which is involved in immune infiltration, and may serve as prognosis biomarkers for breast cancer progression. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
30. Expression Profiles and Prognostic Value of FABPs in Colorectal Adenocarcinomas.
- Author
-
Prayugo, Fidelia Berenice, Kao, Tzu-Jen, Anuraga, Gangga, Ta, Hoang Dang Khoa, Chuang, Jian-Ying, Lin, Li-Chia, Wu, Yung-Fu, Wang, Chih-Yang, and Lee, Kuen-Haur
- Subjects
PROGNOSIS ,FATTY acid-binding proteins ,SOMATOMEDIN ,OVERALL survival ,COLORECTAL cancer - Abstract
Colorectal cancer (CRC) is one of the world's leading causes of cancer-related deaths; thus, it is important to detect it as early as possible. Obesity is thought to be linked to a large rise in the CRC incidence as a result of bad dietary choices, such as a high intake of animal fats. Fatty acid-binding proteins (FABPs) are a set of molecules that coordinate intracellular lipid responses and are highly associated with metabolism and inflammatory pathways. There are nine types of FABP genes that have been found in mammals, which are FABP1–7, FABP9, and FABP12. Each FABP gene has its own roles in different organs of the body; hence, each one has different expression levels in different cancers. The roles of FABP family genes in the development of CRC are still poorly understood. We used a bioinformatics approach to examine FABP family gene expression profiles using the Oncomine, GEPIA, PrognoScan, STRING, cBioPortal, MetaCore, and TIMER platforms. Results showed that the FABP6 messenger (m)RNA level is overexpressed in CRC cells compared to normal cells. The overexpression of FABP6 was found to be related to poor prognosis in CRC patients' overall survival. The immunohistochemical results in the Human Protein Atlas showed that FABP1 and FABP6 exhibited strong staining in CRC tissues. An enrichment analysis showed that high expression of FABP6 was significantly correlated with the role of microRNAs in cell proliferation in the development of CRC through the insulin-like growth factor (IGF) signaling pathway. FABP6 functions as an intracellular bile-acid transporter in the ileal epithelium. We looked at FABP6 expression in CRC since bile acids are important in the carcinogenesis of CRC. In conclusion, high FABP6 expression is expected to be a potential biomarker for detecting CRC at the early stage. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
31. Expression Profile and Prognostic Value of Wnt Signaling Pathway Molecules in Colorectal Cancer.
- Author
-
Wu, Yung-Fu, Wang, Chih-Yang, Tang, Wan-Chun, Lee, Yu-Cheng, Ta, Hoang Dang Khoa, Lin, Li-Chia, Pan, Syu-Ruei, Ni, Yi-Chun, Anuraga, Gangga, and Lee, Kuen-Haur
- Subjects
COLORECTAL cancer ,CELLULAR signal transduction ,WNT signal transduction ,GENE expression ,PROGNOSIS - Abstract
Colorectal cancer (CRC) is a heterogeneous disease with changes in the genetic and epigenetic levels of various genes. The molecular assessment of CRC is gaining increasing attention, and furthermore, there is an increase in biomarker use for disease prognostication. Therefore, the identification of different gene biomarkers through messenger RNA (mRNA) abundance levels may be useful for capturing the complex effects of CRC. In this study, we demonstrate that the high mRNA levels of 10 upregulated genes (DPEP1, KRT80, FABP6, NKD2, FOXQ1, CEMIP, ETV4, TESC, FUT1, and GAS2) are observed in CRC cell lines and public CRC datasets. Moreover, we find that a high mRNA expression of DPEP1, NKD2, CEMIP, ETV4, TESC, or FUT1 is significantly correlated with a worse prognosis in CRC patients. Further investigation reveals that CTNNB1 is the key factor in the interaction of the canonical Wnt signaling pathway with 10 upregulated CRC-associated genes. In particular, we identify NKD2, FOXQ1, and CEMIP as three CTNNB1-regulated genes. Moreover, individual inhibition of the expression of three CTNNB1-regulated genes can cause the growth inhibition of CRC cells. This study reveals efficient biomarkers for the prognosis of CRC and provides a new molecular interaction network for CRC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
32. Prognostic Value of Cardiac Troponin and Risk Assessment in Pediatric Supraventricular Tachycardia.
- Author
-
Yen, Chieh-Ching, Chen, Shou-Yen, Chaou, Chung-Hsien, Wang, Chih-Kai, Yeh, Hsin-Tzu, and Ng, Chip-Jin
- Subjects
SUPRAVENTRICULAR tachycardia ,PROGNOSIS ,TROPONIN ,CHILD patients ,RISK assessment - Abstract
Cardiac troponin I (cTnI) elevation is common in an acute episode of supraventricular tachycardia (SVT). However, there is limited evidence regarding the prognostic value of cTnI and the predictors of SVT recurrence in pediatric patients. We screened the electronic medical records of all pediatric patients presenting to the emergency departments at five Taiwanese hospitals from 1 January 2010 to 31 May 2021. Our primary outcomes were the occurrence of major adverse cardiac events (MACEs) during the follow-up period and 30-day SVT recurrence. A total of 112 patients were included in our study. Of these, 29 (25.9%) patients had positive cTnI values. Patients with cTnI elevation had significantly more complaints of dyspnea (27.6% vs. 7.2%, p = 0.008) and gastrointestinal discomfort (24.1% vs. 4.8%, p = 0.006). There were significantly more intensive care unit admissions (41.4% vs. 16.9%, p = 0.007) among the cTnI-positive group. One MACE was found in the cTnI-negative group. For 30-day SVT recurrence, the cTnI-positive group had a higher recurrence rate, without a statistically significant difference (20.7% vs. 7.2%, p = 0.075). Multivariable logistic regression analysis showed hypotension as an independent predictor of 30-day SVT recurrence (OR = 4.98; Cl 1.02–24.22; p = 0.047). Troponin had low value for predicting the outcomes of pediatric patients with SVT. The only significant predictor for recurrent SVT was initial hypotension. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
33. Analysis of LAGEs Family Gene Signature and Prognostic Relevance in Breast Cancer.
- Author
-
Khoa Ta, Hoang Dang, Tang, Wan-Chun, Phan, Nam Nhut, Anuraga, Gangga, Hou, Sz-Ying, Chiao, Chung-Chieh, Liu, Yen-Hsi, Wu, Yung-Fu, Lee, Kuen-Haur, and Wang, Chih-Yang
- Subjects
GENE families ,PROGNOSIS ,BREAST cancer ,GENE expression profiling ,FOCAL adhesions - Abstract
Breast cancer (BRCA) is one of the most complex diseases and involves several biological processes. Members of the L-antigen (LAGE) family participate in the development of various cancers, but their expressions and prognostic values in breast cancer remain to be clarified. High-throughput methods for exploring disease progression mechanisms might play a pivotal role in the improvement of novel therapeutics. Therefore, gene expression profiles and clinical data of LAGE family members were acquired from the cBioportal database, followed by verification using the Oncomine and The Cancer Genome Atlas (TCGA) databases. In addition, the Kaplan-Meier method was applied to explore correlations between expressions of LAGE family members and prognoses of breast cancer patients. MetaCore, GlueGo, and GluePedia were used to comprehensively study the transcript expression signatures of LAGEs and their co-expressed genes together with LAGE-related signal transduction pathways in BRCA. The result indicated that higher LAGE3 messenger (m)RNA expressions were observed in BRCA tissues than in normal tissues, and they were also associated with the stage of BRCA patients. Kaplan-Meier plots showed that overexpression of LAGE1, LAGE2A, LAGE2B, and LAGE3 were highly correlated to poor survival in most types of breast cancer. Significant associations of LAGE family genes were correlated with the cell cycle, focal adhesion, and extracellular matrix (ECM) receptor interactions as indicated by functional enrichment analyses. Collectively, LAGE family members' gene expression levels were related to adverse clinicopathological factors and prognoses of BRCA patients; therefore, LAGEs have the potential to serve as prognosticators of BRCA patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
34. Impact of the COVID-19 Pandemic on the Loading and Quality of an Emergency Department in Taiwan: Enlightenment from a Low-Risk Country in a Public Health Crisis.
- Author
-
Chen, Jamie Yu-Hsuan, Chang, Feng-Yee, Lin, Chin-Sheng, Wang, Chih-Hung, Tsai, Shih-Hung, Lee, Chia-Cheng, Chen, Sy-Jou, and Kellett, John G.
- Subjects
COVID-19 pandemic ,COVID-19 ,HOSPITAL emergency services ,MEDICAL personnel ,CHEST pain ,PROGNOSIS - Abstract
The impact of the coronavirus disease 2019 (COVID-19) pandemic on health-care quality in the emergency department (ED) in countries with a low risk is unclear. This study aimed to explore the effects of the COVID-19 pandemic on ED loading, quality of care, and patient prognosis. Data were retrospectively collected from 1 January 2018 to 30 September 2020 at the ED of Tri-service general hospital. Analyses included day-based ED loading, quality of care, and patient prognosis. Data on triage assessment, physiological states, disease history, and results of laboratory tests were collected and analyzed. The number of daily visits significantly decreased after the pandemic, leading to a reduction in the time to examination. Admitted patients benefitted from the pandemic with a reduction of 0.80 h in the length of stay in the ED, faster discharge without death, and reduced re-admission. However, non-admitted visits with chest pain increased the risk of mortality after the pandemic. In conclusion, the COVID-19 pandemic led to a significant reduction in low-acuity ED visits and improved prognoses for hospitalized patients. However, clinicians should be alert about patients with chest pain due to their increased risk of mortality in subsequent admission. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
35. Landscape of Mitochondria Genome and Clinical Outcomes in Stage 1 Lung Adenocarcinoma.
- Author
-
Raghav, Lovely, Chang, Ya-Hsuan, Hsu, Yi-Chiung, Li, Yu-Cheng, Chen, Chih-Yi, Yang, Tsung-Ying, Chen, Kun-Chieh, Hsu, Kuo-Hsuan, Tseng, Jeng-Sen, Chuang, Cheng-Yen, Lee, Mei-Hsuan, Wang, Chih-Liang, Chen, Huei-Wen, Yu, Sung-Liang, Su, Sheng-Fang, Yuan, Shin-Sheng, Chen, Jeremy J.W., Ho, Shinn-Ying, Li, Ker-Chau, and Yang, Pan-Chyr
- Subjects
LUNG cancer risk factors ,LUNG cancer prognosis ,ADENOCARCINOMA ,CANCER patients ,CANCER relapse ,CHROMOSOME abnormalities ,CONFIDENCE intervals ,EPIDERMAL growth factor ,HUMAN genome ,LUNG cancer ,MITOCHONDRIA ,MOLECULAR biology ,GENETIC mutation ,ONCOGENES ,SPECTRUM analysis ,SURVIVAL analysis (Biometry) ,TUMOR classification ,TREATMENT effectiveness ,INDIVIDUALIZED medicine ,PSYCHOLOGICAL vulnerability ,DESCRIPTIVE statistics ,SEQUENCE analysis - Abstract
Risk factors including genetic effects are still being investigated in lung adenocarcinoma (LUAD). Mitochondria play an important role in controlling imperative cellular parameters, and anomalies in mitochondrial function might be crucial for cancer development. The mitochondrial genomic aberrations found in lung adenocarcinoma and their associations with cancer development and progression are not yet clearly characterized. Here, we identified a spectrum of mitochondrial genome mutations in early-stage lung adenocarcinoma and explored their association with prognosis and clinical outcomes. Next-generation sequencing was used to reveal the mitochondrial genomes of tumor and conditionally normal adjacent tissues from 61 Stage 1 LUADs. Mitochondrial somatic mutations and clinical outcomes including relapse-free survival (RFS) were analyzed. Patients with somatic mutations in the D-loop region had longer RFS (adjusted hazard ratio, adjHR = 0.18, p = 0.027), whereas somatic mutations in mitochondrial Complex IV and Complex V genes were associated with shorter RFS (adjHR = 3.69, p = 0.012, and adjHR = 6.63, p = 0.002, respectively). The risk scores derived from mitochondrial somatic mutations were predictive of RFS (adjHR = 9.10, 95%CI: 2.93–28.32, p < 0.001). Our findings demonstrated the vulnerability of the mitochondrial genome to mutations and the potential prediction ability of somatic mutations. This research may contribute to improving molecular guidance for patient treatment in precision medicine. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
36. Correlation between auditory brainstem response and hearing prognosis in idiopathic sudden sensorineural hearing loss patients.
- Author
-
Lin, Hung-Che, Chou, Yu-Ching, Wang, Chih-Hung, Hung, Li-Wen, Shih, Cheng-Ping, Kang, Bor-Hwang, Yeh, Wen-Ying, and Chen, Hsin-Chien
- Subjects
- *
DIAGNOSIS of deafness , *AUDITORY evoked response , *SENSORINEURAL hearing loss , *DEAF people , *HEALTH outcome assessment , *BRAIN stem physiology , *STEROID drugs , *DEXTRAN , *BLOOD plasma substitutes , *AUDIOMETRY , *CONVALESCENCE , *PROGNOSIS , *THERAPEUTICS ,THERAPEUTIC use of glucocorticoids - Abstract
Objective: To investigate the latency and amplitude of auditory brainstem response (ABR) and hearing prognosis in patients with idiopathic sudden sensorineural hearing loss (ISSNHL).Methods: Patients with ISSNHL were classified into four different recovery groups. All patients' clinical and demographic features were analyzed. Two-channel ABRs were collected in response to click stimuli at 90dB nHL. ABR amplitudes for wave I and ABR latency for waves I, III, and V were analyzed.Results: One hundred and two patients (54 men and 48 women) were included in the study. Hearing recovery was observed in 72 cases (70.6%). Waves I, III, and V latencies were significantly prolonged in the affected ears compared with the unaffected ears. A smaller wave I amplitude was found in the affected ear compared with the unaffected ear in the three recovery groups. There was a significant association between wave I latency and hearing outcome (p=0.009) with a prolonged trend from complete to slight hearing recovery group.Conclusions: There was a significant correlation between wave I latency and hearing outcome in patients with ISSNHL. The finding may provide diagnostic information and serve as a potential prognostic indicator in patients with ISSNHL. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
37. Tumor Necrosis Is an Indicator of Poor Prognosis Among Hepatoma Patients Undergoing Resection.
- Author
-
Kuo, Fang-Ying, Eng, Hock-Liew, Li, Wei-Feng, Liu, Yueh-Wei, Wang, Chih-Chi, Lin, Chih-Che, Yong, Chee-Chien, and Yen, Yi-Hao
- Subjects
- *
NECROSIS , *HEPATOCELLULAR carcinoma , *CANCER prognosis , *MULTIPLE tumors , *PROGNOSIS - Abstract
Tumor necrosis has been associated with poor prognosis in hepatocellular carcinoma (HCC) patients undergoing liver resection (LR). However, more evidence is needed to clarify this issue. Patients who underwent upfront LR between 2010 and 2018 for newly diagnosed HCC without undergoing neoadjuvant therapy were enrolled in this retrospective study. Tumor necrosis was classified as present or absent according to retrospective examinations. The association between tumor necrosis, pathologic characteristics, overall survival (OS), and recurrence-free survival (RFS) were analyzed. Among 756 patients who underwent LR for HCC, tumor necrosis was present in 279 (36.9%) patients. Compared with patients without tumor necrosis, patients with tumor necrosis had higher proportions of tumors sized >5.0 cm (P < 0.001), multiple tumors (P < 0.001), microvascular or macrovascular invasion (P < 0.001), poorly differentiated or undifferentiated tumors (P < 0.001), and T stage 3 or 4 (P < 0.001) on pathological examination. The presence of tumor necrosis was associated with worse OS and RFS compared with the absence of tumor necrosis: 5-y OS was 56% versus 78% (P < 0.001); 5-y RFS was 42% versus 55% (P < 0.001). In multivariate analysis, the presence of tumor necrosis was an independent factor associated with worse OS (hazard ratio: 1.956; 95% confidence interval: 1.409–2.716; P < 0.001) and RFS (hazard ratio: 1.422; 95% confidence interval: 1.085–1.865; P = 0.011). Tumor necrosis was associated with worse OS and RFS among patients who underwent LR for HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
38. Increase of reduced nicotinamide adenine dinucleotide fluorescence lifetime precedes mitochondrial dysfunction in staurosporine-induced apoptosis of HeLa cells.
- Author
-
Yu, Jia-Sin, Guo, Han-Wen, Wang, Chih-Hao, Wei, Yau-Huei, and Wang, Hsing-Wen
- Subjects
NAD (Coenzyme) ,FLUORESCENCE ,MITOCHONDRIAL physiology ,APOPTOSIS ,HELA cells ,PROGNOSIS ,ADENOSINE triphosphate ,CHEMICAL synthesis - Abstract
In vivononinvasive detection of apoptosis represents a new tool that may yield a more definite diagnosis, a more accurate prognosis, and help improve therapies for human diseases. The intrinsic fluorescence of reduced nicotinamide adenine dinucleotide (NADH) may be a potential optical biomarker for the apoptosis detection because NADH is involved in the respiration for the mitochondrial membrane potential () formation and adenosine-5′-triphosphate (ATP) synthesis, and the depletion of and ATP level is the hallmark of apoptosis. We have previously observed the NADH fluorescence lifetime change is associated with staurosporine (STS)-induced mitochondria-mediated apoptosis. However, its relationship with mitochondrial functions such as , ATP, and oxygen consumption rate is not clear. In this study, we investigated this relationship. Our results indicate that the NADH fluorescence lifetime increased when and ATP levels were equal to or higher than their values of controls and decreased before the depletion of and ATP, and the oxygen consumption rate did not change. These findings suggest that the increased NADH fluorescence lifetime in STS-induced cell death occurred before the depletion of and ATP and activation of caspase 3, and was not simply caused by cellular metabolic change. Furthermore, the NADH fluorescence lifetime change is associated with the pace of apoptosis. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
39. Neuroprognostic Accuracy of Quantitative Versus Standard Pupillary Light Reflex for Adult Postcardiac Arrest Patients: A Systematic Review and Meta-Analysis.
- Author
-
Chih-Hung Wang, Cheng-Yi Wu, Chia-Yu Liu, Carolyn, Tzu-Chun Hsu, Liu, Michael A., Meng-Che Wu, Min-Shan Tsai, Wei-Tien Chang, Chien-Hua Huang, Chien-Chang Lee, Shyr-Chyr Chen, Wen-Jone Chen, Wang, Chih-Hung, Wu, Cheng-Yi, Liu, Carolyn Chia-Yu, Hsu, Tzu-Chun, Wu, Meng-Che, Tsai, Min-Shan, Chang, Wei-Tien, and Huang, Chien-Hua
- Subjects
- *
RECEIVER operating characteristic curves , *REFLEXES , *SENSITIVITY & specificity (Statistics) , *META-analysis , *TIME , *SYSTEMATIC reviews , *PROGNOSIS , *CARDIAC arrest , *DISEASE complications - Abstract
Objectives: An automated infrared pupillometer measures quantitative pupillary light reflex using a calibrated light stimulus. We examined whether the timing of performing quantitative pupillary light reflex or standard pupillary light reflex may impact its neuroprognostic performance in postcardiac arrest comatose patients and whether quantitative pupillary light reflex may outperform standard pupillary light reflex in early postresuscitation phase.Data Sources: PubMed and Embase databases from their inception to July 2020.Study Selection: We selected studies providing sufficient data of prognostic values of standard pupillary light reflex or quantitative pupillary light reflex to predict neurologic outcomes in adult postcardiac arrest comatose patients.Data Extraction: Quantitative data required for building a 2 × 2 contingency table were extracted, and study quality was assessed using standard criteria.Data Synthesis: We used the bivariate random-effects model to estimate the pooled sensitivity and specificity of standard pupillary light reflex or quantitative pupillary light reflex in predicting poor neurologic outcome during early (< 72 hr), middle (between 72 and 144 hr), and late (≧ 145 hr) postresuscitation periods, respectively. We included 39 studies involving 17,179 patients. For quantitative pupillary light reflex, the cut off points used in included studies to define absent pupillary light reflex ranged from 0% to 13% (median: 7%) and from zero to 2 (median: 2) for pupillary light reflex amplitude and Neurologic Pupil index, respectively. Late standard pupillary light reflex had the highest area under the receiver operating characteristic curve (0.98, 95% CI [CI], 0.97-0.99). For early standard pupillary light reflex, the area under the receiver operating characteristic curve was 0.80 (95% CI, 0.76-0.83), with a specificity of 0.91 (95% CI, 0.85-0.95). For early quantitative pupillary light reflex, the area under the receiver operating characteristic curve was 0.83 (95% CI, 0.79-0.86), with a specificity of 0.99 (95% CI, 0.91-1.00).Conclusions: Timing of pupillary light reflex examination may impact neuroprognostic accuracy. The highest prognostic performance was achieved with late standard pupillary light reflex. Early quantitative pupillary light reflex had a similar specificity to late standard pupillary light reflex and had better specificity than early standard pupillary light reflex. For postresuscitation comatose patients, early quantitative pupillary light reflex may substitute for early standard pupillary light reflex in the neurologic prognostication algorithm. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
40. Clinical characteristics and correlation between hearing outcomes after different episodes of recurrent idiopathic sudden sensorineural hearing loss.
- Author
-
Wu, Pei-Hsuan, Lee, Chia-Yi, Chen, Hsin-Chien, Lee, Jih-Chin, Chu, Yueng-Hsiang, Cheng, Li-Hsiang, Wang, Chih-Hung, and Shih, Cheng-Ping
- Subjects
- *
SENSORINEURAL hearing loss , *HYPERBARIC oxygenation , *PROGNOSIS , *VERTIGO , *STEROID drugs , *TREATMENT of deafness , *TREATMENT of hearing disorders , *INTRAVENOUS therapy , *ORAL drug administration , *DEAFNESS , *RETROSPECTIVE studies , *DISEASE relapse , *TREATMENT effectiveness , *HEARING disorders , *AUDIOMETRY ,THERAPEUTIC use of glucocorticoids - Abstract
Objectives: Recurrent idiopathic sudden sensorineural hearing loss (ISSNHL) is a rare disease. In this study, we evaluated the correlations between hearing recovery after the first and recurrent episodes of ISSNHL and characterized the clinical features of different episodes of ISSNHL.Methods: This retrospective study was conducted by reviewing medical records pertaining to the period 2008-2018. A total of 30 patients (16 male, 14 female) who had experienced at least two episodes of ISSNHL were included. All patients were had received steroid therapy (including systemic and IT) and/or hyperbaric oxygen therapy within 2 weeks after the onset of disease. The SDRG's criteria was used for the grading of hearing recovery.Results: The median age at the first and second episode of ISSNHL was 48 and 53.5 years, respectively; a total of 30% of patients presented with vertigo in the first episode and 40% presented with vertigo in the second episode. The hearing outcomes of both episodes showed significant improvement after treatment. The rate of complete recovery after the first and second episodes was 46.67% and 33.33%, respectively. A significant positive correlation was observed between the treatment outcomes of the first and second episodes (r = 0.721, p < 0.001).Conclusion: In ISSNHL, hearing recovery after a recurrent episode is significantly correlated with the hearing outcome after the initial episode (p = 0.042). The treatment outcome of the first episode is a prognostic factor for the outcomes of recurrent episodes. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
41. Cortactin as a potential predictor of second esophageal neoplasia in hypopharyngeal carcinoma.
- Author
-
Lien, Ching-Feng, Hwang, Tzer-Zen, Lin, Tsun-Mei, Liu, Kai-Wen, Lin, Bor-Shyh, Wang, Chih-Chun, Yang, Chuan-Chien, and Yeh, Shyh-An
- Subjects
- *
ESOPHAGEAL cancer , *HYPOPHARYNGEAL cancer , *SQUAMOUS cell carcinoma , *CARCINOMA , *ESOPHAGEAL tumors , *GENE amplification , *MULTIVARIATE analysis , *AGE distribution , *HEAD tumors , *LONGITUDINAL method , *NECK tumors , *PROGNOSIS , *LOGISTIC regression analysis , *PROPORTIONAL hazards models , *RETROSPECTIVE studies , *KAPLAN-Meier estimator , *SECONDARY primary cancer , *ODDS ratio - Abstract
Objective: Hypopharyngeal carcinoma has a very poor prognosis. The high incidence of second esophageal neoplasia is one of the major causes. To establish an efficient follow-up scheme for increasing the diagnostic yield and reducing the adverse impact of second esophageal neoplasia on survival, the purpose of this study was to explore a biomarker to predict second esophageal neoplasia.Methods: In this retrospective cohort study, consecutive tissue specimens from those patients who underwent tumor resection between September 2007 and October 2015 were collected. Gene amplification was performed by real-time PCR. The expression of cortactin was evaluated by immunohistochemistry. The predictive risk factors of developing second esophageal neoplasia and prognostic factors related to survival were analyzed.Results: A total of 187 patients were included with a mean follow-up of 48months (12-118months). Second esophageal tumors were found in 53 (28.3%), including 41 (21.9%) esophageal squamous cell carcinoma and 12 severe dysplasia. The results of multivariate analyses revealed that age (OR 2.81, 95% CI 1.16-6.78), cortactin overexpression (OR 2.49, 95% CI 1.17-5.33), and stage IV versus I (OR 6.49, 95% CI 1.68-25.18) were independent predictors of second esophageal neoplasia, and second esophageal neoplasia (HR 1.78, 95% CI 1.05-3.01) was an independent predictor of overall survival.Conclusion: This is the first report to identify a potential biomarker for predicting second esophageal neoplasia in patients with hypopharyngeal carcinoma. In those patients with cortactin overexpression and younger age (≤60years old), close surveillance for second esophageal neoplasia is required. In addition, the real effect of cortactin overexpression on development of primary esophageal carcinoma is required to be validated in a large cohort study. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.